Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells

por Wu, Chung-Pu, Li, Yen-Ching, Murakami, Megumi, Hsiao, Sung-Han, Lee, Yun-Chieh, Huang, Yang-Hui, Chang, Yu-Tzu, Hung, Tai-Ho, Wu, Yu-Shan, Ambudkar, Suresh V.
Publicado 2023